Fosravuconazole
Fosravuconazole
Study the efficacy of fosravuconazole as a potential new, safe, and affordable treatment for patients with eumycetoma
current phase of drug development




updated 21 Feb 2025
Treating eumycetoma (fungal mycetoma) is a challenge. The antifungals ketoconazole and itraconazole are currently among the limited number of therapies available, especially in sub-Saharan Africa, but they are expensive, not very effective, and have serious side effects. People with advanced eumycetoma may undergo amputations, or die as a result of delayed or ineffective treatment. Safe, effective antifungal treatments for eumycetoma that are appropriate for use in rural settings are urgently needed.
Fosravuconazole, an orally bioavailable azole developed for onychomycosis by Eisai Ltd (Japan), could be an effective and affordable treatment for eumycetoma. Its pharmacokinetic properties are favourable, and its toxicity is low. Fosravuconazole, a prodrug, is rapidly converted to ravuconazole, which has been shown to have potent in vitro activity against one of the causative agents of eumycetoma, M. mycetomatis.
In 2017, the Mycetoma Research Centre (MRC), a WHO Collaborating Centre in Khartoum, Sudan, launched the first-ever double-blind, randomized clinical trial for eumycetoma treatment. The trial studied the efficacy of treating mild-to-moderate-sized lesions with a weekly dose of fosravuconazole over a period of 12 months, compared to daily treatment with itraconazole, the current standard of care, both in combination with surgery at 6 months. The results showed that fosravuconazole is safe, patient-friendly, and effective in treating eumycetoma. Its significant advantages for patients compared to the current standard of care include weekly versus daily dosing, minimal interactions with other medicines, and the ability to be taken either with or without food.
Project updates
2024
The results of the Phase II clinical trial were published in The Lancet Infectious Diseases in November 2024 and showed that treatment with either of the two dose levels of fosravuconazole was not superior to itraconazole, and the two dose levels had a numerically lower efficacy. However, fosravuconazole presented no new safety signals, and its lower pill burden and reduced risk of drug-drug interactions compared with relatively expensive and inaccessible itraconazole suggests further research into effective treatments with a shorter duration and higher cure rate, without the need for surgery, is warranted.
2023
The results of the Phase II clinical trial were presented at the 13th European Congress on Tropical Medicine and International Health (ECTMIH), held in November 2023 in Utrecht, Netherlands. The clinical study report was finalized and results are expected to be published in 2024. The long-term follow-up study assessing the recurrence rate of mycetoma in clinical trial participants in the Phase II trial was stopped in 2023 due to socio-political unrest in Sudan. A total of 51 participants were included in the follow-up study. Recurrence rates remained low and no serious adverse events were reported.
2022
The database lock for the Phase II clinical trial was conducted in March 2022. The top-line results were presented at the 21st Congress of the International Society for Human and Animal Mycology (ISHAM), held in September 2022 in New Delhi, India. The clinical study report is under review and expected to be finalized in early 2023.
To determine the long-term post-treatment recurrence of eumycetoma, an observational study has begun at the Mycetoma Research Center in Khartoum, Sudan. It will follow patients who did not have a recurrence by the end of the Phase II clinical trial.
2021
Although challenged by the COVID-19 pandemic which resulted in a country-wide lockdown in Sudan, patient follow-up continued in 2021. The study was reviewed by the data and safety monitoring board in late 2021, and it was decided that the study could be stopped, and the results analysed in early 2022. A strategy was developed to register fosravuconazole in Sudan, initially on a compassionate or conditional basis in advance of full registration. In addition, an access strategy is under development.
2020
By March 2020, 104 patients had been enrolled in the study, but the target was to enrol 165 patients by the end of the year. Recruitment was put on hold while a second interim analysis is prepared. After this analysis is completed in mid-2021, the clinical trial may be terminated or may progress until full completion of the recruitment is concluded in 2022. Discussions with regulatory authorities in Sudan to obtain conditional approval for compassionate use of the drug will also begin in 2021.
2019
The first-ever double-blind study to determine whether the new chemical entity fosravuconazole could be an effective and affordable treatment for eumycetoma is ongoing. By January 2020, 101 patients had been enrolled in the study, which should reach the targeted enrollment of 165 patients by the end of 2020. A Data and Safety Monitoring Board (DSMB) meeting was held in 2019 after the study reached the threshold for interim analysis (84 participants). The DSMB reviewed study data and decided to continue with all three treatment arms (200 mg vs 300 mg of fosravuconazole weekly vs daily itraconazole).
2018
Following slower than anticipated recruitment, a protocol review and amendment was conducted in 2018 to extend the inclusion criteria in relation to lesion size and site, and age range of participants. By January 2019, 84 patients had been enrolled, reaching the threshold for interim analysis. This analysis will determine which of two treatment arms will be retained for the remainder of the trial (200mg vs 300mg of fosravuconazole weekly).
2017
After receiving regulatory and ethical approval in March 2017, the Mycetoma Research Centre, a WHO Collaborating Centre, began recruiting patients into the first-ever double-blind, randomized Phase II/III clinical trial for eumycetoma. The clinical trial, which plans to recruit 138 patients, evaluates the efficacy of the anti-fungal fosravuconazole in moderate lesions in comparison with the current treatment, itraconazole.
The primary objective of this single-centre study conducted in Sudan is to demonstrate the superiority of fosravuconazole over itraconazole after 12 months’ treatment. By the end of 2017, 20 patients had been enrolled into the trial, a pace of enrolment that was slower than anticipated. In 2018, a satellite site will be established to screen more patients and refer them for treatment and care.
2016
Protocols of the phase II/III aiming at assessing the comparative efficacy, safety, and tolerability of fosravuconazole in patients with eumycetoma caused by Madurella mycetomatis were finalized in 2016 and recruitment of patients (with a target of 136 participants) should start early 2017. An interim analysis will be conducted at three months.
2015
DNDi is currently preparing for a Phase II/III randomized controlled trial that will be conducted with the WHO Collaborating Centre on Mycetoma in Khartoum to study the efficacy of fosravuconazole in moderate lesions in comparison with the current treatment, itraconazole. The primary objective of this double-blind, randomized, single-centre study will be to demonstrate superiority of fosravuconazole over itraconazole after 12 months’ treatment in patients with eumycetoma caused by Madurella mycetomatis.
News & resources
- 28 April 2025 – World’s only research centre for flesh-eating infection ransacked in Sudan, The Telegraph
- 24 April 2025 – Sudan war destroys world’s only research centre on skin disease mycetoma: director, France 24
- 21 April 2025 – A balancing act: Navigating the advantages and challenges of pioneering mycetoma treatment in Sudan – A landmark trial by the Mycetoma Research Center, PLOS Neglected Tropical Diseases
- 29 October 2024 – The Science Explained: Evaluating an alternative treatment regimen for fungal mycetoma
- 8 August 2024 – Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial, Lancet Infectious Diseases
- 8 May 2024 – Conflict’s impact on a neglected disease, Health Check
- 19 March 2024 – Oral drug promises better treatment for mycetoma, Nature Africa
- 28 February 2024 – Can non-profits beat antibiotic resistance and soaring drug costs?, Nature
- 23 November 2023 – Mycetoma: Neglected but not Forgotten
- 23 November 2023 – World’s first clinical trial for devastating fungal disease mycetoma shows efficacy of new, promising treatment
- 23 November 2023 – Medikament für ärmste Kranke der Welt gefunden, Tages Anzeiger
- 23 November 2023 – Utafiti wa tiba ya ugonjwa wa Madura Foot, BBC News Swahili
- 23 November 2023 – Sudan could be winning war against mycetoma cases, Africa Science News
- 23 November 2023 – Flesh-eating disease leading to amputation gets treatment hope, Bloomberg
- 23 November 2023 – Cheap over-the-counter nail drug found to work on crippling flesh-eating disease, The Guardian
- 6 October 2023 – DNDi 2023 Projects of the Year recognize contributions of DNDi teams and partners working to deliver medical innovations for people affected by Chagas disease and mycetoma
- 10 May 2023 – Un climat plus propice aux maladies causées par des champignons, RTS
- 19 June 2017 – Clinical trial for a better treatment for mycetoma starts in Sudan
Clinical trials documents
- Eisai Co., Ltd., Japan
- Erasmus MC, The Netherlands
- Institute of Endemic Diseases (IEND), Khartoum University, Sudan
- Mycetoma Research Centre (MRC), Sudan
- Eisai Co., Ltd.
- ,Japan
- Erasmus MC
- ,The Netherlands
- Institute of Endemic Diseases (IEND), Khartoum University
- ,Sudan
- Mycetoma Research Centre (MRC)
- ,Sudan
- Eisai Co., Ltd., Japan
- Erasmus MC, The Netherlands
- Institute of Endemic Diseases (IEND), Khartoum University, Sudan
- Mycetoma Research Centre (MRC), Sudan
- Japan - Global Health Innovative Technology Fund (GHIT Fund)
- Switzerland - Swiss Agency for Development and Cooperation (SDC)
- Switzerland - Republic and Canton of Geneva, International Solidarity Service
- The Netherlands - Dutch Ministry of Foreign Affairs (DGIS)
- UK - UK International Development
- Médecins Sans Frontières International
- Médecins Sans Frontières Switzerland
- Nationale Postcode Loterij & Dutch Postcode Lottery
- Other private foundations and individuals
Stay connected
Get our latest news, personal stories, research articles, and job opportunities.